Last reviewed · How we verify
mRNA-1273.712
mRNA-1273.712, developed by ModernaTX, Inc., is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its advanced mRNA technology, which provides a robust platform for rapid development and scalability. The primary risk is the potential for increased competition as the patent expires in 2028.
At a glance
| Generic name | mRNA-1273.712 |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA-1273.712 CI brief — competitive landscape report
- mRNA-1273.712 updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI